Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...

• Recursion Pharmaceuticals’ stock rises 8% in pre-market to $5.08 after positive trial results. • The Phase 1B/2 TUPELO trial indicates significant reductions in polyp burden for REC-4881, enhancing ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...

BOSTON--(BUSINESS WIRE)--Factorial Inc. (Factorial), an industry leader in solid-state battery technology, today announced the shipment of its first solid-state lithium-metal battery cells for drone ...

Can a small Massachusetts start-up perfect a battery that would make electric vehicles cheaper and more convenient than conventional cars? Can a small Massachusetts start-up perfect a battery that ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...